Investors
Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment
Bryan, Garnier & Co: Oscar Haffen Lamm
Rx Securities: Joseph Hedden
Carnegie: Arvid Necander
Pareto Securities: Chien-Hsun Lee
ABG Sundal Collier: Alexander Krämer
Redeye: Fredrik Thor
April 15, 2024
Annual Report 2023
May 3, 2024
Interim Report Q1 2024 (7:00am CEST)
Share
Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden
Phone: +46 8 679 72 10
E-mail: info@egetis.com
